Drug Profile
Quizartinib companion diagnostic - Daiichi Sankyo/Invivoscribe Technologies
Alternative Names: AC220 companion diagnostic; LeukoStrat® CDx FLT3 Mutation Assay - Daiichi Sankyo/InvivoscribeLatest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Genoptix
- Developer Daiichi Sankyo Company; Invivoscribe Technologies
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Acute myeloid leukaemia
Most Recent Events
- 11 Dec 2023 Efficacy data from the phase-III QuANTUM-First trial in Acute Myeloid Leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition Session (ASH-Hem-2023)
- 21 Jul 2023 Registered for Acute myeloid leukaemia (Diagnosis) in USA
- 24 Oct 2022 Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 mutation assay to select patients with newly diagnosed FLT3-ITD positive AML